On October 20, 2025, Anixa Biosciences announced that the Chinese National Intellectual Property Administration issued Patent Number ZL2020800215666, covering key aspects of its breast cancer vaccine technology. The patent protects the vaccine’s use of human α‑lactalbumin as an immunogenic target and extends protection into the 2040s in China.
The issuance follows the company’s earlier U.S. and Canadian patent filings and expands its global intellectual‑property estate, giving Anixa exclusive rights to develop, manufacture, and commercialize the vaccine in a market with one of the highest breast‑cancer incidences. The patent strengthens the company’s position as it prepares to present full Phase 1 data at the San Antonio Breast Cancer Symposium on December 11, 2025.
By securing this Chinese patent, Anixa solidifies its strategic partnership with Cleveland Clinic and positions itself to pursue international development and licensing opportunities. The milestone is a critical step toward monetizing the vaccine platform and could unlock future revenue streams in a high‑growth market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.